Urothelial Carcinoma of the Renal Pelvis and Ureter Clinical Trials

5 recruiting

Frequently Asked Questions

Common questions about Urothelial Carcinoma of the Renal Pelvis and Ureter clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting

Bladder EpiCheck European Haematuria Study

Urothelial Carcinoma BladderUrothelial Carcinoma of the Renal Pelvis and UreterHematuria+2 more
Nucleix Ltd.800 enrolled5 locationsNCT06818136
Recruiting
Phase 1Phase 2

Sacituzumab Govitecan Plus EV in Metastatic UC

Metastatic Urothelial CarcinomaUrothelial CancerBladder Cancer+1 more
Dana-Farber Cancer Institute106 enrolled1 locationNCT04724018
Recruiting
Phase 2Phase 3

Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma

Urothelial Carcinoma of the Renal Pelvis and UreterTransitional Cell Cancer of the Renal Pelvis and Ureter
University of British Columbia70 enrolled4 locationsNCT06124976
Recruiting
Phase 2

Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma

Urothelial Carcinoma BladderUrothelial Carcinoma of the Renal Pelvis and UreterUrothelial Carcinoma Urethra+1 more
Nagoya University43 enrolled1 locationNCT06983210
Recruiting
Phase 2

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

Urothelial CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma of the Renal Pelvis and Ureter+1 more
Mabwell (Shanghai) Bioscience Co., Ltd.60 enrolled2 locationsNCT06823427
Recruiting

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

Urothelial CarcinomaUrothelial Carcinoma of the Renal Pelvis and UreterUrothelial Carcinoma Recurrent+5 more
UroGen Pharma Ltd.400 enrolled22 locationsNCT05874921